Partnership Provides Standards for MSI Assay

Gene editing and gene modulation technologies company Horizon Discovery Group has developed a set of precisely defined cell line-derived reference standards to support Biocartis’ recently launched Idylla™ microsatellite instability (MSI) Assay1.

The Assay (RUO), allowing qualitative detection of seven monomorphic homopolymer biomarkers to identify human cancers with MSI, uses formalin-fixed, paraffin-embedded (FFPE) tissue sections from human cancer tissue, from which nucleic acids are extracted, amplified and then analysed.

Dr Chris Lowe, Head of Research Operations, Horizon Discovery, commented: “Horizon pioneered the development of genetically defined, well-characterised cell line derived reference standards and this collaboration with Biocartis further validates our position as the leader in the field. Our teams are continually innovating to expand this range and we are proud to offer a sustainable source of reference material to support accurate assay results when examining MSI on the Idylla™ platform.”

Erwin Sablon, VP Alliance Management & Partnerships of Biocartis, said: “The collaboration between Biocartis and Horizon has contributed greatly to the successful market launch of the Idylla™ MSI Assay in July 2018. We continue to be impressed with the quality of Horizon’s reference standards.”

The CE-marking of the Idylla™ MSI Assay for in vitro diagnostic use in colorectal cancer is anticipated in the first half of 2019.

1. The Idylla™ MSI Assay is intended for research use only (RUO) and is not approved for use as a diagnostic assay.